N-(6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide

Catalog No. :
ACRRZP783
CAS No. :
1187968-47-3
Molecular Formula :
C16H20BN3O3
Molecular Weight :
313.17

IUPAC Name:N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide

N-(6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide
IUPAC NameN-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide
Molecular FormulaC16H20BN3O3
Molecular Weight313.17
SMILESCC(NC1=NC=C2C=C(B3OC(C)(C)C(C)(C)O3)C=CC2=N1)=O
InChI KeyNOSPVCLFUXUDOQ-UHFFFAOYSA-N
SynonymN-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)acetamide;Acetamide, N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-quinazolinyl]-
CAS No.1187968-47-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRRZP783 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACRRZP783 route product structure diagram
    ACRRZP7831187968-47-3
Inquiry

2. ACRRZP783 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOEGH891 route compound structure diagram
    ACOEGH891882670-92-0 In Stock
  4. Then
  5. ACRRZP783 route product structure diagram
    ACRRZP7831187968-47-3
Inquiry

Comments (0)